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TACROLIMUS RESCUE THERAPY FOR RENAL ALLOGRAFT 
REJECTION-FIVE-YEAR EXPERIENCE l 
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Over the 5 year period from 7/1411989 until 5/2411994, 
we have attempted graft salvage with tacrolimus con-
version in a total of 169 patients (median age 33 years, 
range 2-75 years) with ongoing rejection on baseline 
CsA immunosuppression after failure of high dose cor-
ticosteroids and/or antilymphocyte preparations to re-
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verse rejection. The indications for conversion to ta-
crolimus were ongoing, biopsy confirmed rejection in 
all patients. The median interval to tacrolimus conver-
sion was 2 months (range 2 days to 55 months; mean 
4.3±2.6 months) after transplantation. All patients had 
failed high dose corticosteroid therapy and 144 (85%) 
of the 169 patients had received at least one course of 
an antilymphocyte preparation plus high dose corti-
costeroid therapy prior to conversion. Twenty-eight 
patients (17%) were dialysis-dependent at the time of 
conversion owing to the severity of rejection. With a 
mean follow-up of 30.0±2.4 months (median 36.5 
months, range 12-62 months), 125 of 169 patients (74%) 
have been successfully rescued and still have func-
tioning grafts with a mean serum creatinine (SCR) of 
2.3± 1.1 mgJdl. Of the 144 patients previously treated 
224 TRANSPLANTATION Vol. 63, NO.2 
with antilymphocyte preparations, 117 (81%) were sal-
vaged. Of the 28 patients on dialysis at the time of 
conversion to tacrolimus, 13 (46%) continue to have 
functioning grafts (mean SCR 2.15:1:0.37 mgldl) at a 
mean follow-up of 37.3:1: 16.7 months. In the 125 pa-
tients salvaged, prednisone doses have been lowered 
from 28.0:1:9.0 mgld (median 32, range 4-60 mgld) pre-
conversion to 8.5±4.1 mg/d (median 12 mgld, range 
2.5-20 mgld) postconversion. Twenty-eight patients 
(22.4%) are currently receiving no steroids. This 5 year 
experience demonstrates that tacrolimus has sus-
tained efficacy as a rescue agent for ongoing renal 
allograft rejection. Based on these data, we recom-
mend that tacrolimus be used as an alternative to the 
conventional drugs used for antirejection therapy in 
renal transplantation. 
Tacrolimus is a new immunosuppressant that is currently 
undergoing clinical trials for efficacy in renal transplanta-
tion. It has been previously reported that this agent is safe 
and effective for primary renal transplantation, with appar-
ent advantages that include steroid tapering and mono-
therapy in up to 60% of recipients (1-3). Perhaps even more 
striking is the utility of this drug as a salvage agent for 
refractory renal allograft rejection. We previously reported in 
a series of 77 patients with refractory acute rejection on 
baseline cyclosporine (CsA)· therapy that graft salvage with 
tacrolimus conversion could be achieved in 74% of cases (4). 
This group included 61 patients who had been unsuccessfully 
treated with antilymphocyte preparations in an attempt to 
reverse ongoing rejection, of whom 79% were salvaged. This 
early study provided relatively short term follow-up (mean 
13.9 months). Since that initial report, we have entered an 
additional 92 patients for a total of 169 renal transplant 
recipients who have been converted to tacrolimus in order to 
attempt graft salvage. The overall period of the entire study 
was from July 14, 1989 until May 24, 1994, with a current 
mean follow-up of 30.0±2.4 months (range 12-62 months). 
The results of this expanded experience with tacrolimus con-
version for recalcitrant renal allograft rejection are reported 
herein. 
MATERIALS AND METHODS 
Patients. Between July 14, 1989 and May 24, 1994, 169 patients 
(98 male, 71 female) with a mean age of36.2=13.1 years (range 2-75 
years) with ongoing allograft rejection under baseline CsA immuno-
suppression were converted to tacrolimus immunosuppression. The 
causes of end stage renal disease (ESRD) included insulin dependent 
diabetes mellitus (lOOM) in 48 patients, glomerulonephritis in 43, 
hypertension in 14. adult polycystic kidney disease in 12, systemic 
lupus erythematosus in 7 patients, reflux nephropathy in 6, renal 
hypoplasia or dysplasia in 5, focal segmental glomerulosclerosis 
(FSGS) in 4. and posterior urethral valves, Wegener's granulomato-
sis, calculous disease. and connective tissue disease in 2 patients 
each. In 22 patients the cause of ESRD was unknown. One hundred 
and thirty-eight patients (82%) were primary transplant recipients 
and 31 (18%) had been retransplanted (21 second. 7 third, 2 fourth. 
and 1 fifth transplant). One hundred and thirty-two patients (78%) 
were recipients of cadaver (CAD) grafts and 37 (22%) were from 
* Abbreviations: ACR, acute cellular rejection; AZA, azathiopnne; 
CsA. cyclosporine; CAD. cadaver; CMV. cytomegalovirus; ESRD, end 
stage renal disease; FSGS. focal segmental glomerulosclerosIs: 
100M. insulin dependent diabetes mellitus; LO. living donor: PTLD. 
posttransplant lymphoproliferatlve disorder; ::3CR. serum creatlnlne. 
living donors (LDl. Nineteen patients had received combined kidney-
pancreas allografts. 
All 169 patients converted to tacrolimus had uncontrolled rejec-
tion on primary CsA-based immunosuppressive therapy. Mainte-
nance immunosuppression had consisted of CsA and prednisone in 
all patients, either with (n=117, 69%) or without (n=52, 31%) aza-
thioprine (AZA). Two patients had previously been placed on mYCD-
phenolate mofetil in unsuccessful attempts to reverse rejection. The 
majority of the patients in this series (156 of169, 92%) were referred 
to our institution from 32 other centers where they were deemed to 
be losing their grafts owing to the severity of their rejection. The 
participating centers included Akron City Hospital, Allegheny Gen-
eral Hospital, Beaumont Hospital, Borgess Medical Center, New 
York Hospital, Duke University Medical Center, Geisenger Medical 
Center, Hartford Hospital, Henry Ford Hospital, Hospital of the 
University of Pennsylvania, Lehigh Valley Hospital, Medical College 
of Virginia, Montefiore Medical Center, Pritzker Medical Center, St. 
Elizabeth Hospital, Stanford University Medical Center, SUNY 
Medical Center, Sutter Memorial Medical Center, Thomas Jefferson 
University Hospital, UCLA Medical Center, University of Arkansas, 
University ofIDinois, University of Kansas, University of Maryland, 
University of Massachussetts, University of Miami, University of 
Michigan, University of Minnesota, University of North Carolina, 
University of Southern California, University of Tennessee, and 
Washington Hospital Center. In all cases, careful consideration was 
given to ensure that all patients had been maintained on maximized 
but safe and tolerable CsA dosing, Previous antirejection therapy 
had been administered to all 169 patients in the form of bolus high 
dose corticosteroids. A total of144 of the 169 patients (85%) had also 
receiv.ed at least one course of a monoclonal (OKT3) and/or polyclonal 
(ATG or ATGAM) antilymphocyte preparation. Forty-seven patients 
(28%) had received 2 or more courses of OKT3 prior to tacrolimus 
conversion and 51 patients (30%) received both OKT3 and a poly-
clonal antilymphocyte preparation prior to tacrolimus. 
Tacrolimus conversion protocol. In all cases prior to conversion to 
tacrolimus, allograft dysfunction secondary to technical causes was 
ruled out by doppler ultrasound and radionuclide flow study of the 
allograft. Pathologic specimens of biopsy material were reviewed 
from the referring center and core biopsies of the allograft were 
repeated at our own institution in all patients to verify the continu-
ing presence of ongoing rejection prior to conversion to tacrolimus. 
Acute cellular rejection (ACR) was present in biopsy specimens of all 
169 patients prior to conversion, including 62 patients (37%) whose 
biopsies also revealed a vascular component of rejection (lymphocytic 
inflltration in arterial walls, intraglomerular hemorrhage, and/or 
infarction). In addition, 16 patients demonstrated ACR on biopsy of 
kidneys that remained dialysis-dependent from the time of trans-
plantation. AB previously described (4), all patients underwent a 
simple switch ("clean conversion") from CsA to tacrolimus. Tacroli-
mus was given at a standard daily oral dose of 0.2-0.3 mg/kglday in 
divided doses every 12 hr starting 12-24 hr after the last CsA dose 
had been administered. Oosage adjustments were based upon mon-
itoring of trough serum tacrolimus levels by ELISA (5) in the early 
(1989-early 1994) portion of the study to achieve 12-hr trough levels 
of 1.0 to 2.0 nglml, and in the latter part of the study (mid 1994-
present) by whole blood MElA - IMx assay (6, 7) to achieve 12-hr 
trough levels of 15-20 nglml. and also according to clinical and 
biochemical parameters. Data were analyzed for statistical signifi-
cance by two tailed Student's t test or chi square analysis when 
appropriate. 
RESULTS 
The criteria for successful graft salvage with tacrolimus 
included a return to or improvement in baseline SCR. andlor 
improvement on follow up renal biopsy, andlor freedom from 
dialysis if the patient was dialysis dependent at the time of 
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failing primary CsA based immunosuppression with ongoing 
rejection were converted to tacrolimus at an average of 
4.3=2.6 months (range 2 days to 55 months) following trans-
plantation. With a mean follow-up of 30.0=2.4 months (me-
dian 36.5 months, range 12 to 62 months), 159 of 169 patients 
(94%) remain alive and 125 of 169 patients (74%) have 
achieved graft salvage according to the aforementioned cri-
teria. Kaplan-Meier patient and graft survivals from the time 
of tacrolimus conversion are shown in Figure 1. All 169 
patients converted to tacrolimus displayed ongoing cellular 
rejection on preconversion allograft biopsy (Table 1). Of 
these, 62 patients (37%) also had evidence of a vascular 
component of rejection and 16 patients (9%) had never 
achieved initial graft function. Ninety-one of the 169 patients 
(54%) had elements of acute cellular rejection (ACR) only. 
The outcome of tacrolimus conversion according to the pre-
conversion biopsy diagnosis is shown in Table 1. Of the 91 
patients with ACR only on preconversion biopsy, 70 (77%) 
achieved graft salvage after tacrolimus conversion. Of the 62 
patients with elements of both ACR plus vascular rejection 
on pre conversion biopsy, 47 (75%) also achieved graft salvage 
(P=NS vs. ACR alone). Of the 16 patients with primary graft 
nonfunction who remained on dialysis from the time of trans-
plantation until conversion, 8 (50%) were salvaged by con-
version to tacrolimus (P=O.l, ACR vs. ACR + vascular rejec-
tion vs ACR + primary nonfunction). An additional 12 
patients with primary graft function prior to conversion be-
came dialysis dependent as a result of severe ongoing rejec-
tion during initial CsA therapy. Thus, of 169 patients, a total 
of 28 patients (17%) were dialysis dependent at the time of 
tacrolimus conversion. Thirteen of these patient (46%) cur-
rently have functioning grafts, with a mean serum creatinine 
of 2.15=0.37 mgldl at a mean follow-up of 37.3=16 months 
(range 18 to 62 months) postconversion. 
Tacrolimus conversion was successful in 96 of 133 (72%) 
CAD and in 29 of 36 (80%) LD recipients (P=NS). Successful 
rescue was also obtained in 107 of 138 (78%) primary trans-
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FIGURE 1. Kaplan Meier patient and graft survival of 169 patients 
converted from esA to tacrolimus therapy for refractory renal allo-
graft rejection. Calculations are based on events from the time of 
conversion to tacrolimus. Numbers in parentheses mdicate patients 
at risk at each tIme pomt. 
TABLE 1. Outcome of tacrolimus conversion in 169 renal 
transplant recipients failing primary esA therapy 
Preconversion biopsy Number of Success (%)" Pta. (%) 
Acute cellular rejection 91 (54%) 70 (77%) 
Vascular rejection 62 (37%) 47 (75%) 
Acute cellular rejection with 16 (9%) 8 (50%) 
primary nonfunction 
Total 169 125 (74%) 
a P=0.1 
transplants, 1 of 2 (50%) fourth transplants, and in the one 
fifth transplant patient (P=0.14). Of the 19 recipients of 
combined kidney-pancreas allografts, 18 (95%) were success-
fully rescued. Table 2 shows the influence of time elapsed 
between transplantation and tacrolimus conversion on the 
likelihood of successful conversion. If conversion took place 
earlier than 2 or 3 months posttransplantation, there was no 
significant difference in success rates compared to conversion 
>2 months or >3 months posttransplantation (P=0.5 and 
0.13, respectively). However, conversion was more likely to 
be successful if undertaken within 6 months of transplanta-
tion (77% success) as compared with >6 months after trans-
plantation (50%, P=0.OO6). 
Preconuersion immunosuppression and tacrolimus conuer-
sian. All 169 patients in the study were receiving CsA-ste-
roid based immunosuppression either in combination with 
azathioprine (n= 117) or without azathioprine (n=52). Immu-
nosuppression with either triple therapy (CsA-steroid-AZA) 
or double therapy (CsA-steroids) did not influence the likeli-
hood of graft salvage after tacrolimus conversion (triple ther-
apy: 90 of 117, 77%; double therapy: 35 of 52, 67%; P=0.26). 
Both patients treated with mycophenolate mofetil prior to 
referral were successfully salvaged with tacrolimus. In addi-
tion to receiving high dose corticosteroid therapy to treat 
ongoing rejection, 144 of 169 patients (85%) also received at 
least one course of an antilymphocyte preparation (OKT3, 
ATG, and/or ALG, average length of treatment 14.2=5.8 
days). Forty-seven patients received two or more courses of 
OKT3 prior to conversion. Eighty-nine patients had received 
OKT3 only, 4 patients either ALG or ATG only and 51 pa-
tients received a course ofOKT3 and a course of ALG or ATG . 
Of the 144 patients treated with antilymphocyte antibody 
prior to conversion, 117 (81%) were salvaged with tacrolimus 
conversion. 
TABLE 2. Effect of interval to tacrolimus conversion following 
renal transplantationa 
ConversIOn after Success (%) P KTX(mo) 
<2 67/86 (78%) 
0.5 
>2 61183 (73%) 
<3 921120 (77%) 
0.13 
>3 32149 (65%) 
<6 1141147 (77%) 
0.006 
"6 11122 (50%) 
" Mean interval to conversion: 4.:.1:=2.6 rno post-Tx: median mter-
val: 2 mo \ range: ~ days-.'l5 mo, 
-
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Renal function before and after tacrolimus conversion. 
Twenty-eight patients were dialysis dependent at the time of 
referral for tacrolimus conversion owing to the severity of the 
ongoing rejection; of these, 13 (46%) were successfully sal-
vaged and came off dialysis. With a mean follow up of 
37.3:t16.7 months (range 18 to 62 months) following conver-
sion, these 13 patients have SCR levels of 1.6, 1.6, 1.7, 1.8, 
1.8, 1.9, 2.2, 2.4, 2.5, 2.5, 2.6, 2.6, and 2.8 mg/dl (mean SCR 
2.15:t0.37). Excluding the 28 patients who were on dialysis 
at the time of tacrolimus conversion, the mean SCR prior to 
conversion in the successful switches was 3.1:t 1. 7 mg/dl. The 
mean SCR after tacrolimus conversion was 2.3:t1.1 mg/dl 
(P=0.0002 vs. preconversion) for patients not on dialysis at 
conversion. Of the 125 successful conversions, 112 patients 
were not on dialysis prior to conversion. Table 3 shows the 
sequence of improvement in renal function following tacroli-
mus conversion in these patients. Excluding the 28 patients 
on dialysis prior to conversion, there were a total of 81 pa-
tients with initial SCR :s3 mg/dl, of whom 68 (84%) were 
successfully rescued, compared with 44 of 60 patients (73%) 
with an initial SCR >3 mg/dl. Although the quality of initial 
renal function trended toward a higher likelihood of success-
ful conversion, this did not reach statistical significance 
(P=0.18). 
Immunosuppression after tacrolimus rescue therapy. All 
169 patients were receiving steroid therapy prior to conver-
sion from CsA to tacrolimus. Table 4 shows the preconversion 
and postconversion prednisone doses. In the 125 patients 
successfully rescued, the average preconversion prednisone 
dose of28.0:t9.0 mg/day has been lowered to 6.6:t5.1 mg/day, 
and 28 patients (22%) of the 125 with functioning grafts are 
on tacrolimus monotherapy. Of the 97 patients still taking 
prednisone, 87 have had their prednisone doses lowered from 
the preconversion dose and 10 patients remain on the same 
preconversion dose. Eighty-seven of the 125 patients (70%) 
were also on AZA at the time of conversion. Of these, 6 (7%) 
have had an increase in the AZA, 24 (28%) have had a 
decrease, 18 (20%) remain on the same AZA dose, and 39 
(45%) have stopped AZA. One patient initially on mycophe-
nolate mofetil required its discontinuation because of leuko-
penia; the other patient initially taking mycophenolate 
mofetil continues on it, and both patients still have function-
ing grafts. In the 125 patients with functioning grafts, the 
mean tacrolimus dose has decreased from 19.3:t9.1 mg/d at 
conversion to 11.3::!:6.8 mg/d at last follow-up (P<O.Ol). Pre-
and postconversion tacrolimus levels were not compared for 
the purpose of statistical analysis because of the variability 
in the method of detection during the 5 years of the study. 
Morbidity and mortality. Since this series was initiated in 
1989, there have been a total of 10 deaths. 7 of which oc-
TABLE 3. Renal function after conversion from esA to tacrolimusu 
Time alter Scr (mgJdll Range P V8. time 0 
converSion n 
0 3.09::1.7 0.9-11.4 112 
1 wk 3.12:: 1.8 0.5-9.5 112 0.8 
12 mo 2.13::0.8 0.9-5.2 95 <0.01 
24 mo 2.20:: 1.0 1. O-B. 0 51 <0.01 
:l6 mo 2.13=0.9 1.2-5.6 28 0.005 
·HI mo 2.05=0.6 1.3-3.5 16 ll.02 
" Excluding patients on dialysis at the time of conversion. 
TABLE 4. Prednisone dose before and after tacrolimus conversion 
No. patients (%) 
Pred (MgID) Preconversion P08tconversion (n=125) (n=125) 
0 0 (0%) 28 (22%) 
2.5 0 (0%) 9 (7%) 
5 0 (0%) 24 (19%) 
7.5 o (0%) 19 (15%) 
10 12(10%) 23 (18.5%) 
12.5 5 (4%) 12 (10%) 
15 6 (5%) 7 (6%) 
20 33 (26%) 3 (2.5%) 
>20 69 (55%) 0 (0%) 
Mean Dose 28.0:t9.0 6.6::!:5.1 
curred in patients who had an unsuccessful attempt at graft 
salvage with tacrolimus conversion. In the initial series re-
ported in 1994, there were a total of 6 deaths due to post-
transplant lymphoproliferative disorder (PTLD) in 2 patients 
(one of whom was found to have had unsuspected PTLD at 
the time of conversion), sepsis in 1, tuberculosis in 1 (patient 
exposed to TB at referring center prior to transfer), and 
intracranial hemorrhage in 1 (4). The sixth patient died after 
returning to dialysis 8 months after failing tacrolimus con-
version. In this expanded report of 169 patients, there have 
been an additional 4 deaths. Three of these deaths occurred 
in patients from the original series who were initially suc-
cessfully salvaged. One of these 3 patients died of over-
whelming sepsis with a functioning graft 27 months follow-
ing successful conversion. A second patient died of a 
myocardial infarction 16 months after successful conversion. 
A third patient returned to dialysis 3 months after initial 
successful conversion and died on dialysis (etiology un-
known). A fourth patient who was not successfully rescued 
died of a myocardial infarction one week after conversion. 
This patient was the only mortality of the 92 additional 
patients converted to tacrolimus since the original series 
ended in February 1993. Overall, 4 of the 10 deaths (PTLD in 
2, sepsis in 1. and TB in 1) were likely related to overimmu-
nosuppression prior to conversion, although an additive ef-
fect of tacrolimus to the immunosuppressive risk in these 
patients must certainly be considered. In retrospect, tacroli-
mus conversion in these 4 patients (all of whom failed con-
version) was likely ill-advised. None of the remaining 6 
deaths could be temporally or causally related to tacrolimus 
conversion. Excluding the patients who died. 39 patients 
referred to us for tacrolimus conversion had prior complica-
tions including cytomegalovirus (CMV) disease requiring an-
tiviral therapy (ganciclovir and/or CMV hyperimmune glob-
ulin) in 12. renal artery stenosis requiring angioplasty in 6, 
lymphocele requiring drainage in 5, urine leak requiring 
surgical correction in 4, ureteral obstruction in 4, perforated 
duodenal ulcer following high dose steroid therapy for rejec-
tion in 1, cardiac arrest in 1, cutaneous herpes virus infection 
in 1, Candida esophagitis in 1, segmental renal infarction 
with no sequelae in 1. Clostridium difficile colitis in 1. aseptic 
menigitis secondary to OKT3 in 1, and myocardial infarction 
in 1. Thirty of these 39 patients (7770) were subsequently 
rescued. There were 35 complications following tacrolimus 
conversion, including new onset diabetes mellitus in 9 pa-
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ication), urinary tract infection in 6, CMV disease requiring 
antiviral (ganciclovir) therapy in 6, deep vein thrombosis in 
2,line sepsis in 2, renal artery stenosis requiring angioplasty 
in 2, bacterial pneumonia in 2, cecal perforation in 1, disease 
recurrence (membranoproliferative glomerulonephritis) in 1, 
proteinuria in 1, gout requiring colchicine and allopurinol 
therapy in 1, epistaxis in 1, and a cerebrovascular accident in 
1. None of these postconversion complications resulted in 
patient death. 
Causes of graft loss after tacrolimus conversion. There 
were 44 failures oftacrolimus conversion in this group of 169 
patients. Twenty-two patients had ongoing renal allograft 
rejection that was refractory to tacrolimus conversion. 
Eleven patients had repeat rejection episodes after initial 
successful rescue and lost their grafts. Five of these 11 were 
late immunologic graft losses due to chronic rejection at 8, 24, 
26, 28, and 48 months, respectively, following initial success-
ful conversion in patients from the original series of 77 pre-
viously reported (4). Three of these five patients had ele-
ments of chronic rejection on preconversion biopsy. Six of 11 
were among the 92 additional patients converted to tacroli-
mus since our original series, and they have experienced late 
immunologic graft loss, one each at 5, 6, 6, 9, 10, and 20 
months following initial successful conversion. Eight pa-
tients with primary allograft nonfunction with superimposed 
rejection were not salvaged, two patients lost their graft due 
to noncompliance, and one patient died with a functioning 
graft. 
DISCUSSION 
One of the most exciting developments of the new age of 
immunosuppressive therapy in the 1990s is the emergence of 
novel agents that have the ability to reverse ongoing rejec-
tion episodes in renal allograft recipients receiving tradi-
tional baseline immunotherapy with CsA (4, 8-12). Tacroli-
mus (formerly known as FK506) has previously been shown 
to provide salvage of refractory allograft rejection in 74% of 
patients on baseline CsA therapy who have failed either high 
dose corticosteroid therapy and/or antilymphocyte therapy in 
short term follow-up (4). Clearly, the utility of an agent which 
provides salvage of ongoing rejection must be proven in the 
long term and should have sustained efficacy in sufficient 
numbers of patients. Since our initial report in 1994, we have 
experience with an additional 92 patients referred to our 
center for tacrolimus conversion. The profiles of patients in 
this expanded study are very similiar to those in our earlier 
study, in that the majority (1441169,85%) of the patients had 
failed prior treatment with antilymphocyte preparations and 
a subset of 281169 (17%) of the patients had rejections so 
severe as to necessitate ongoing dialysis therapy prior to 
conversion. Overall, graft salvage was obtained in 125 of 169 
patients (74%), which is identical to the salvage rate obtained 
in our earlier reported series of 77 patients (4), Significantly, 
this was with a mean follow-up of 30 months. reflecting the 
longevity of the salvage effect. The subset of 92 patients who 
were converted to tacrolimus since our original report were 
all referred from outside institutions where the patients were 
deemed to be losing their grafts owing to ongoing rejection. In 
this subgroup of 92 patients (mean follow-up 19 months. 
range 12 to 29 months), 77 patients (84';() have been success-
fully rescued. In attempting to Identify patients who would 
not benetit from conversion to tacrolimus. we stratified the 
patients according to initial biopsy findings. We have previ-
ously found that grafts with chronic rejection without any 
acute component are unlikely to benefit from tacrolimus con-
version (13). Although in our earlier series we found that the 
presence of vascular rejection conferred an approximate 20% 
disadvantage to the likelihood of salvage with tacrolimus, 
this was not statistically significant in our expanded experi-
ence. The patients with ACR alone experienced a 77% sal-
vage rate, whereas those with components of vascular rejec-
tion experienced a 75% salvage rate (P=NS). In the group of 
patients with ACR superimposed on primary allograft non-
function, the salvage rate of 50% was comparable to the rate 
of 40% previously reported (4). Overall, however, the differ-
ence in salvage rates with respect to the findings on precon-
version biopsy did not reach statistical significance (P=O.l). 
Another important feature that appears to be unique to 
tacrolimus as a salvage agent when compared with other 
agents (8, 9, 12) is its ability to provide graft salvage in 
patients who have been on dialysis owing to the severity of 
rejection. Long-term graft salvage was obtained in 13 of 28 
such patients (46%) resulting in stable allograft function 
(mean SCR of2.15 mg/dl) with a mean follow-up of37.3±16.7 
months. Overall postconversion renal function in all of the 
125 patients salvaged in this series was 2.3±1.1 mg/d!. Fur-
thermore, with follow-up up to 48 months, the SCR has 
continued to improve in patients successfully salvaged, per-
haps indicating a beneficial effect oftacrolimus in preventing 
the onset of chronic rejection in some patients. The degree of 
initial renal function impairment did not statistically influ-
ence the likelihood of successful conversion in that patients 
with an SCR of <3 experienced a salvage rate of 84% com-
pared with 73% in patients initially having an SCR >3 (ex-
cluding the 28 patients on dialysis at the time of conversion) 
(P=0.18). Another potential factor that may have influenced 
the likelihood of successful rescue was the interval between 
the time of transplantation and tacrolimus conversion. In our 
earlier series we found no differences in the success rates 
whether tacrolimus conversion was performed before or after 
2, 3, or 6 months following transplantation. In that earlier 
series, only 11 patients had been switched to tacrolimus >6 
months posttransplantation. In the current series, there ap-
pears to be a slight but statistically significant advantage to 
conversion <6 months after transplantation in that 1141147 
(77%) experienced graft salvage compared with 11122 (50%) 
success if conversion was attempted >6 months after trans-
plantation (P=O.006). Conversion performed before or after 2 
or 3 months following transplantation did not appear to 
influence the outcome. Probably more important than the 
timing of conversion are the findings on preconversion bi-
opsy, in which the presence of chronic rejection or ACR with 
primary allograft nonfunction portends a worse prognosis (4, 
13). One of the most striking observations in our early expe-
rience with tacrolimus rescue was the ability to taper and 
even stop prednisone therapy in approximately 20% of pa-
tients successfully salvaged (4), This trend was maintained 
in this expanded experience. and currently 28/125 (22%) pa-
tients with functioning grafts are on tacrolimus mono-
therapy. 
As a result of our expanded experience. we have learned 
that tacrolimus can provide effective salvage of ongoing renal 
allograft rejection for patients on conventional CsA·based 
immunotherapy. The utility of esA as a primary immuno-
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suppressive agent has stood the test oftime for its efficacy in 
renal transplantation (14-17). However, there is a group of 
patients who experience refractory allograft rejection in 
whom CsA is no longer effective even when combined with 
antilymphocytic therapy to attempt rejection reversal (16, 
17). In addition to the now well-established graft salvage 
effects of tacrolimus, several other agents have shown initial 
promise as rescue agents, including mycophenolate mofetil 
(8,9), 15-deoxyspuergualin (12), and perhaps sirolimus (10). 
In the latter case report, sirolimus was effective in amelio-
rating rejection in a patient who was requiring dialysis ther-
apy (10). Further experience with this agent in primary and 
rescue therapy is anticipated. Whether these agents will 
provide long-lived salvage rates and afford the opportunity to 
wean steroids after rescue (such as is possible with tacroli-
mus) remains to be determined. 
The reasons for the salutary effects oftacrolimus on estab-
lished renal allograft rejection remain speculative but may 
include additional or distinct immunosuppressive activities 
of tacrolimus that have not yet been identified at the molec-
ular level (18). One such hypothesis may be that lymphocytes 
that have been previously inhibited by CsA now escape inhi-
bition, permitting certain cell subsets to undergo clonal pro-
liferation and perhaps become "tolerant" to the effects ofCsA. 
It is hoped that further investigation will elucidate the mech-
anisms by which tacrolimus appears to be unique in its 
ability to provide effective long-term reversal of renal allo-
graft rejection with what appears to be minimal attrition in 
the long term due to immunologic causes. We currently rec-
ommend that tacrolimus conversion be considered an alter-
native to antilymphocycte preparations for steroid resistant 
rejection in CsA based regimens. Tacrolimus is clearly also 
effective in salvaging rejecting grafts that have failed antilym-
phocyte therapy. With mandated reduction in costs and hospi-
tal lengths of stay upon us, minimizing the use of antilympho-
cyte preparations, both in terms of their expense and potential 
complications, would be most desirable, as long as equivalent 
graft survival rates can be achieved. Agents such as tacrolimus 
may provide a unique opportunity to address some of these 
concerns and may prove to be more cost effective than the 
traditional methods by which steroid resistant episodes have 
been treated in the past. The addition of tacrolimus to the 
immunosuppressive armamentarium has provided transplant 
physicians with a much needed alternative to the conventional 
drugs used for renal allograft rejection therapy. 
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